Loading stock data…
PEPG
$1.75+0.11 (+6.71%)
Market ClosedLast close May 1
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PepGen Inc. in the Healthcare sector is trading at $1.75. The stock is currently near its 52-week low of $1.01, remaining 56.4% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why PEPG maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.75
Potential Upside
5%
Whystock Fair Value$1.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-co...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$114.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.81%
Volume
Today's trading volume
1.87M
Recent News
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway
PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what management characterized as encouraging safety, splicing, and functional trend data. F
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
PepGen Inc.'s (NASDAQ:PEPG) largest shareholders are individual investors with 39% ownership, private equity firms own 36%
Key Insights PepGen's significant individual investors ownership suggests that the key decisions are influenced by...